BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29428730)

  • 1. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
    Zhou J; Chen J; Yu H
    Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
    Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
    J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
    Zou Y; Ge M; Wang X
    Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
    Guan S; Liu YY; Yan T; Zhou J
    Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
    White MD; Chan L; Antoon JW; Beckman BS
    Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
    Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
    Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
    French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
    J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
    Beljanski V; Lewis CS; Smith CD
    Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
    Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
    Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
    Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
    Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
    Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
    Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth.
    Dai L; Bai A; Smith CD; Rodriguez PC; Yu F; Qin Z
    Mol Cancer Ther; 2017 Dec; 16(12):2724-2734. PubMed ID: 28939554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
    Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
    Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel sphingosine kinase inhibitor induces autophagy in tumor cells.
    Beljanski V; Knaak C; Smith CD
    J Pharmacol Exp Ther; 2010 May; 333(2):454-64. PubMed ID: 20179157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
    Dai L; Smith CD; Foroozesh M; Miele L; Qin Z
    Int J Cancer; 2018 May; 142(10):2153-2162. PubMed ID: 29277894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
    Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
    Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sphingosine kinase 2 inhibitor ABC294640 inhibits cervical carcinoma cell growth.
    Xu L; Jin L; Yang B; Wang L; Xia Z; Zhang Q; Xu J
    Oncotarget; 2018 Jan; 9(2):2384-2394. PubMed ID: 29416779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
    Xu L; Zhang Y; Gao M; Wang G; Fu Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
    Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
    Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.